Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT05815745

“Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment” (PROTECT-HF)

“Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment” (PROTECT-HF) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT05815745.

📅 15 Jul 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05815745
Sponsor
Imperial College London
Start
2023-06-05
ClinicaliQ Trial Snapshot
  • “Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment” (PROTECT-HF) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT05815745.
  • What is being tested: PROTECT-HF compares right ventricular (RV) pacing—the established standard treatment for bradycardia—against physiological pacing approaches to determine which strategy produces better clinical outcomes in patients requiring permanent pacemaker implantation.
  • Patient eligibility overview: The trial recruits patients with bradycardia who require permanent pacemaker therapy, though specific inclusion/exclusion criteria would determine whether patients have atrioventricular block, sick sinus syndrome, or other conduction abnormalities requiring intervention.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The PROTECT-HF multi-centre randomised controlled trial will compare two different pacing approaches for treating patients with slow heart rates. In it the investigators will compare a long-standing standard approach for pacing; right ventricular pacing, with a new form of pacing, physiological pacing (His and Left bundle area pacing) in 2600 patients. Patients will be allocated at random to receive either right ventricular pacing or physiological pacing. Endpoint measurements will be undertaken at baseline, and at six-monthly intervals post-randomisation. Treatment allocation will be blinded to the endpoint assessor and the patient.…

Eligibility Snapshot
  • We will recruit patients who are referred for clinically indicated pacemaker implantation Inclusion Criteria:
  • Adults aged over 18 with left ventricular ejection fraction >35% and one or more of the following guideline based ventricular pacing indications: 1. Permanent or intermittent 3rd degree AV block 2. Permanent or intermittent Mobitz type II AV block 3. First Degree AV block with a pacing indication 4. Slow chronic Atrial Fibrillation or Proposed AV node ablation 5. Bifascicular block with a pacing indication 6. Trifascicular block with a pacing indication 7. Wenckebach with a pacing indication

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Clinical Brief
New heart disease and strokes plan to saves thousands of lives
Cardiology / Cardiovascular · NHS England · 07 Jul 2026
A new national framework aims to reduce premature deaths from heart disease and strokes by 25% over the next decade, requiring implementation…
View brief →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy
Cardiology / Cardiovascular · 30 Mar 2026
Covers indications for cardiac pacing and cardiac resynchronization therapy (CRT) • Provides guidance on device selection, implantation techniques, and optimization • Addresses…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →